Table 2. Safety profile – Number of subjects requiring treatment with epinephrine.
Active | Placebo | |
---|---|---|
Initial escalation day | 2/19 | 0/9 |
Build-up visits | 0 | 0 |
Home dosing | 0 | 1 |
OFC | 0/16 | 3/9 |
OFC = oral food challenge
Active | Placebo | |
---|---|---|
Initial escalation day | 2/19 | 0/9 |
Build-up visits | 0 | 0 |
Home dosing | 0 | 1 |
OFC | 0/16 | 3/9 |
OFC = oral food challenge